Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ALT is 18 and suggests 209% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell